# Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

> **NCT06951841** · PHASE4 · NOT_YET_RECRUITING · sponsor: **China Medical University, China** · enrollment: 31 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Liposome Irinotecan
- **DRUG:** Platinum
- **DRUG:** Tislelizumab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06951841
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951841, "Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06951841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*